$ZIVO News

Zivo Bioscience CFO Keith R. Marchiando Resigns, Effective Dec. 19; William A. Sullivan Named Interim Successor

ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses

Zivo Bioscience Q2 EPS $(0.43) Misses $(0.41) Estimate, Sales $53.400K Miss $150.000K Estimate

ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO’s Immune-Enhancing Compounds in Poultry

University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry

ZIVO Bioscience to Present at The Microcap Conference 2025

ZIVO Bioscience Reports Progress with Coccidiosis Treatment Licensing Opportunities

Insider Buying: Zivo Bioscience Inc (ZIVO) CEO Acquires Shares

Director and 10% Owner Christopher Maggiore Acquires 31,336 Shares of Zivo Bioscience Inc (ZIVO)

ZIVO Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler Chickens

ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q2 2024

Zivo Bioscience Strengthens Board with New Director Appointment

Major Global Animal Health Company Launches 42-Day Confirmatory Study with ZIVO Bioscience’s Coccidiosis Treatment in Broiler Chickens

Zivo Bioscience Enhances Equity Incentive Plans for Leadership

Zivo Bioscience downgraded to Hold from Buy at Maxim (yesterday)

Maxim Group Downgrades Zivo Bioscience to Hold

Maxim gets more bearish on Zivo Bioscience, downgrades shares

Zivo Bioscience Announces Results From Month-Long Coccidiosis Trial In Broiler Chickens; Says All Test Groups Demonstrated Statistically Significant Benefit In Broiler Health Under Simulated Commercial Conditions